A redox-sensitive switch in the macrophage nucleus regulates acute phase inflammatory injury

巨噬细胞核中的氧化还原敏感开关调节急性期炎症损伤

基本信息

  • 批准号:
    10631088
  • 负责人:
  • 金额:
    $ 55.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

SUMMARY This application is based on the discovery that reactive oxygen and nitrogen species (RONS) within the nucleus of macrophages are powerful signals regulating the polarization of the early immune response and, in particular, the activation of the acute phase of inflammation. Specifically, we found that the promoters of a subset of pro-inflammatory NFκB-target genes, while remaining constitutively accessible, are muted by association with SOCS1, a redox sensitive protein that binds and depletes incoming p65 NFκB. This mechanism simultaneously prevents inflammatory tissue injury during homeostasis as well as provides a rapid and specific pathway to mobilizing aggressive innate immune cells to hunt and kill highly proliferative pathogenic microbes. NOS1-derived nitric oxide (NO) displaces SOCS1 by S-nitrosylation licensing the transcription of acute pro-inflammatory NFκB-target genes. Because H2O2 (ROS) can modify cysteines similarly to NO, we hypothesize that oxidative stress in the nucleus mimics NO, displacing SOCS1 from regulatory regions of pro-inflammatory genes as well as preventing its de novo deposition thereby extending the acute phase of inflammation and preventing the transition to inflammatory resolution and tissue healing. Clinically, this exacerbates pulmonary tissue injury and elevates the risk of ARDS in patients with underlying oxidative stress caused by old age, smoking, autoimmunity, or other conditions. Interestingly, we found that although suppressing nuclear NO or ROS eliminates much of the inflammatory tissue injury in response to LPS, the ability of mice to control K. pneumoniae infection remains intact, indicating that targeting nuclear NO and ROS with existing compounds may be clinically useful to prevent at-risk patients from evolving to ARDS. Currently, ARDS prevention and management is accomplished by the use of powerful immunosuppressive drugs that compromise the ability of the patient to fight infection. In this regard, this proposed project has the potential to advance a long sought goal in the field that is finding ways to suppress inflammatory tissue injury and ARDS while preserving the ability of innate immune cells to eliminate infectious agents intact.
总结 该应用基于活性氧和氮物质(RONS) 在巨噬细胞的细胞核内是调节早期细胞极化的强大信号。 免疫应答,特别是炎症急性期的激活。 具体来说,我们发现促炎性NFκ B靶基因的启动子, 虽然保持组成型可接近,但通过与SOCS 1,氧化还原敏感的 结合并消耗传入p65 NFκB的蛋白质。该机制同时防止 炎症组织损伤在稳态以及提供了一个快速和具体的途径 动员攻击性先天免疫细胞来猎杀高度增殖性病原体 微生物NOS 1衍生的一氧化氮(NO)通过S-亚硝基化取代SOCS 1, 急性促炎性NFκ B靶基因的转录。因为H2 O2(ROS)可以修饰 半胱氨酸类似于NO,我们假设细胞核中的氧化应激模拟NO, 将SOCS 1从促炎基因的调控区中置换出来,并阻止其降解, 新生沉积,从而延长炎症的急性期并防止转化 炎症消退和组织愈合。临床上,这会加重肺组织损伤 并增加了老年引起的潜在氧化应激患者的ARDS风险, 吸烟、自身免疫或其他疾病。有趣的是,我们发现,尽管抑制了 核内NO或ROS消除了大部分响应于LPS的炎性组织损伤, 小鼠控制K.肺炎感染保持完整,表明靶向核 NO和ROS与现有的化合物可能是临床上有用的,以防止风险患者 发展成ARDS。目前,ARDS的预防和管理是通过使用 强效免疫抑制药物,损害患者抵抗感染的能力。在 在这方面,本拟议项目有可能推进该领域长期追求的目标, 正在寻找抑制炎性组织损伤和ARDS的方法,同时保留 先天免疫细胞,以消除感染原完好无损。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marcelo G Bonini其他文献

245 - Human Mitochondrial SOD2 and Bacterial SOD A Incorporated with Iron Become Prooxidant Peroxidases
  • DOI:
    10.1016/j.freeradbiomed.2015.10.292
  • 发表时间:
    2015-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Douglas Ganini;Rnobert M. Petrovichb;Lori L Edwards;Janine H Santos;Marcelo G Bonini;Ronald P Mason
  • 通讯作者:
    Ronald P Mason
122 - SOD2 Promotes the Metabolic Reprogramming and Sustains the Warburg Effect Via AMPK-Dependent Signaling in Cancer
  • DOI:
    10.1016/j.freeradbiomed.2015.10.163
  • 发表时间:
    2015-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marcelo G Bonini;Peter C Hart;Mao Mao;Andre L de Abreu;Kristine Ansenberger-Fricano;Dede N Ekoue;Douglas Ganini;Alan M Diamond;Janine H. Santos
  • 通讯作者:
    Janine H. Santos
165 Ablation of NNOS/NOS1 Leads to the Suppression of the Systemic Inflammatory Response via Suppressor of Cytokine Signaling (SOCS-1) Upregulation
  • DOI:
    10.1016/j.freeradbiomed.2012.10.221
  • 发表时间:
    2012-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Saqib Baig;Farnaz Garcia;Kristine Fricano;Jing Deng;Mao Mao;John Christman;Saurabh Chatterjee;Michelle Block;Richard Minshall;Richard Ye;Benjamin Gantner;Marcelo G Bonini
  • 通讯作者:
    Marcelo G Bonini
Free Radical Metabolism by Cytochrome P4502E1 and NADPH Oxidase Activation Forms Protein Radicals and Tyrosine Nitration in ObesityAssociated Nonalcoholic Fatty Liver Disease
  • DOI:
    10.1016/j.freeradbiomed.2010.10.460
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Saurabh Chatterjee;Douglas Ganini DaSilva;Jinjie Jiang;Marcelo G Bonini;Fabian Leinisch;Maria Kadiiska;Ronald P Mason
  • 通讯作者:
    Ronald P Mason
MnSOD Regulation of AMPK- Mediated Transition toGlycolysis in Breast Cancer
  • DOI:
    10.1016/j.freeradbiomed.2012.10.100
  • 发表时间:
    2012-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Kristine Ansenberger-Fricano;Mao Mao;Paula D. Green;Andrew Hall;Andre Kajdacsy-Balla;Janine A Santos;Marcelo G Bonini
  • 通讯作者:
    Marcelo G Bonini

Marcelo G Bonini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marcelo G Bonini', 18)}}的其他基金

Arsenic suppresses progesterone receptor signaling and promotes tamoxifen resistance and metastasis of ER+ breast cancer
砷抑制孕激素受体信号传导并促进 ER 乳腺癌的他莫昔芬耐药性和转移
  • 批准号:
    10662054
  • 财政年份:
    2022
  • 资助金额:
    $ 55.58万
  • 项目类别:
A redox-sensitive switch in the macrophage nucleus regulates acute phase inflammatory injury
巨噬细胞核中的氧化还原敏感开关调节急性期炎症损伤
  • 批准号:
    10451112
  • 财政年份:
    2022
  • 资助金额:
    $ 55.58万
  • 项目类别:
Environmental Arsenic in the Subtype Specification of Breast Cancer
乳腺癌亚型规范中的环境砷
  • 批准号:
    10252934
  • 财政年份:
    2020
  • 资助金额:
    $ 55.58万
  • 项目类别:
Environmental Arsenic in the Subtype Specification of Breast Cancer
乳腺癌亚型规范中的环境砷
  • 批准号:
    10488608
  • 财政年份:
    2020
  • 资助金额:
    $ 55.58万
  • 项目类别:
Environmental Arsenic in the Subtype Specification of Breast Cancer
乳腺癌亚型规范中的环境砷
  • 批准号:
    10204605
  • 财政年份:
    2020
  • 资助金额:
    $ 55.58万
  • 项目类别:
MNSOD ACETYLATION PROMOTES CANCER STEM CELL PHENOTYPES IN BREAST CANCER
MNSOD 乙酰化促进乳腺癌干细胞表型
  • 批准号:
    10221632
  • 财政年份:
    2018
  • 资助金额:
    $ 55.58万
  • 项目类别:
MNSOD ACETYLATION PROMOTES CANCER STEM CELL PHENOTYPES IN BREAST CANCER
MNSOD 乙酰化促进乳腺癌干细胞表型
  • 批准号:
    10193167
  • 财政年份:
    2018
  • 资助金额:
    $ 55.58万
  • 项目类别:
MnSOD Acetylation Promotes Cancer Stem Cell Phenotypes in Breast Cancer
MnSOD 乙酰化促进乳腺癌干细胞表型
  • 批准号:
    9763487
  • 财政年份:
    2018
  • 资助金额:
    $ 55.58万
  • 项目类别:
MNSOD ACETYLATION PROMOTES CANCER STEM CELL PHENOTYPES IN BREAST CANCER
MNSOD 乙酰化促进乳腺癌干细胞表型
  • 批准号:
    10380372
  • 财政年份:
    2018
  • 资助金额:
    $ 55.58万
  • 项目类别:
MNSOD ACETYLATION PROMOTES CANCER STEM CELL PHENOTYPES IN BREAST CANCER
MNSOD 乙酰化促进乳腺癌干细胞表型
  • 批准号:
    10453720
  • 财政年份:
    2018
  • 资助金额:
    $ 55.58万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.58万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 55.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了